WHO issued its first guidance for countries that provide drugs to offer HIV, known as antiretrovirals (ARVs) to protect people who do not have the virus, but at high risk of HIV infection.
Pre-exposure prophylaxis (CEPR)
Guidance is based on the results of clinical trials showing that the reception of HIV-negative people daily dose of oral antiretrovirals as pre-exposure prophylaxis (CEPR) in order to reduce the risk of infection for humans is safe and effective for HIV prevention. Research initiatives iPrEX showed that the use CEPR may reduce the number of HIV infections among men who have sex with men, about 40% and up to 73% among those who take medications regularly. Research Partners PrEP showed 75 percent protection among serodiscordant couples (couples in which one person with HIV-positive) in Kenya and Uganda.
A wide range of results indicates the potential benefits of the CEPR, but also about the importance of its combination with the constant use of condoms, and frequent testing and counseling and treatment for HIV infection, sexually transmitted diseases.
They also emphasize the importance of daily medication. For many people at high risk of HIV infection, punctilious observance of the prescribed treatment regimen can be challenging. Therefore, the next goal is to establish how best to deliver CEPR those who will use it in "real life" in order to ensure the necessary compliance requirements and maximize the benefits to public health.
Projects on the use of pre-exposure prophylaxis in
For a better understanding of how to best contribute to the CEPR combination HIV prevention program, WHO strongly recommends that countries wishing to enact the CEPR, first create a small-scale projects that will help public health professionals better understand and realize its potential benefits. These projects will be provided ARVs to people at high risk of HIV infection. These may include non-infected men or women who have changed their sex, have sex with men who are at high risk of HIV infection. The aim is to identify the groups who benefit the most from the CEPR, and establish how best to deliver them to those services.
WHO will assess the results of these projects, along with changing scientific data. The results will help determine the best way to include guidance on the CEPR in the future the combined WHO guidelines on the use of antiretroviral drugs for prevention and treatment of HIV infection, which is expected to release in summer 2013.
tags: med-news-pro.blogspot.com, med-news-pro, med newspro, med-news blogspot
Pre-exposure prophylaxis (CEPR)
Guidance is based on the results of clinical trials showing that the reception of HIV-negative people daily dose of oral antiretrovirals as pre-exposure prophylaxis (CEPR) in order to reduce the risk of infection for humans is safe and effective for HIV prevention. Research initiatives iPrEX showed that the use CEPR may reduce the number of HIV infections among men who have sex with men, about 40% and up to 73% among those who take medications regularly. Research Partners PrEP showed 75 percent protection among serodiscordant couples (couples in which one person with HIV-positive) in Kenya and Uganda.
A wide range of results indicates the potential benefits of the CEPR, but also about the importance of its combination with the constant use of condoms, and frequent testing and counseling and treatment for HIV infection, sexually transmitted diseases.
They also emphasize the importance of daily medication. For many people at high risk of HIV infection, punctilious observance of the prescribed treatment regimen can be challenging. Therefore, the next goal is to establish how best to deliver CEPR those who will use it in "real life" in order to ensure the necessary compliance requirements and maximize the benefits to public health.
Projects on the use of pre-exposure prophylaxis in
For a better understanding of how to best contribute to the CEPR combination HIV prevention program, WHO strongly recommends that countries wishing to enact the CEPR, first create a small-scale projects that will help public health professionals better understand and realize its potential benefits. These projects will be provided ARVs to people at high risk of HIV infection. These may include non-infected men or women who have changed their sex, have sex with men who are at high risk of HIV infection. The aim is to identify the groups who benefit the most from the CEPR, and establish how best to deliver them to those services.
WHO will assess the results of these projects, along with changing scientific data. The results will help determine the best way to include guidance on the CEPR in the future the combined WHO guidelines on the use of antiretroviral drugs for prevention and treatment of HIV infection, which is expected to release in summer 2013.
tags: med-news-pro.blogspot.com, med-news-pro, med newspro, med-news blogspot
No comments:
Post a Comment